Industry
What the Hims & Hers GLP-1 pivot tells patients about access and cost
Hims & Hers posted a $92M Q1 2026 loss as it wound down its compounded GLP-1 supply chain and pivoted to branded Wegovy and Zepbound. Here's what the shift means for patients who relied on lower-cost compounded options.
4 min read · Updated 2026-05-25
Peptide GPS publishes educational information, not medical advice. We don't sell, prescribe, or recommend specific medications, dosages, or providers. Always discuss any therapy with a licensed clinician.
Key takeaways
- Hims & Hers reported a $92M net loss in Q1 2026, on revenue of $608M (+4% year over year)
- The loss was driven largely by a $33M restructuring charge for winding down its compounded GLP-1 supply chain
- The company entered distribution partnerships with Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) to offer branded products
- The FDA resolved the semaglutide shortage in February 2025 and tirzepatide shortage in December 2024, ending the legal basis for large-scale compounded GLP-1 production
- Compounded GLP-1s were only permissible during shortage conditions — they are not FDA-approved products
What actually changed at Hims & Hers
Hims & Hers built a major part of its weight-loss business around , offered at prices substantially lower than branded Wegovy. This was a fast-growing revenue line.
In May 2026, the company announced it would stop advertising compounded products and transition its weight-loss platform to branded medications. To do that, it entered distribution agreements with Novo Nordisk and Eli Lilly — deals that come with lower margins for Hims & Hers compared to the in-house compounding model it was running.
Investors reacted negatively. The stock dropped roughly 10% around the Q1 earnings announcement, per Reuters reporting in May 2026.
Why compounded GLP-1s were available in the first place
This context matters for understanding why the pivot happened when it did.
Under Section of the FD&C Act, compounding pharmacies are generally prohibited from preparing products that are "essentially copies" of commercially available, drugs. The exception: when a drug is on the FDA Drug Shortages List, compounders can legally prepare equivalent formulations for individual patients.
Semaglutide injection products entered shortage in 2022, driven by surging demand for Ozempic and Wegovy. That shortage condition allowed compounding pharmacies — including those supplying telehealth platforms like Hims & Hers — to legally fill the gap.
The FDA resolved the shortage in December 2024 and the semaglutide shortage in February 2025. Once the shortage was resolved, the legal basis for compounding those products at scale effectively ended. The FDA's April 2026 clarification confirmed this and specified that semaglutide+B12 combinations — a popular compounded formulation — may be considered essentially copies of approved products, limiting 503A compounders to four or fewer such prescriptions per calendar month.
What this means if you were using compounded semaglutide
If you were getting compounded semaglutide through a telehealth platform, you should expect to hear about changes. Large-scale compounded GLP-1 supply chains are winding down.
Your options now depend on your specific situation:
- Branded Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved; cost and insurance coverage vary significantly by plan
- Some patients may qualify for manufacturer savings programs — Novo Nordisk and Eli Lilly each have patient assistance programs; ask your prescriber or visit the manufacturer's website
- The Wegovy pill (oral semaglutide 25 mg) is now FDA-approved for weight management and represents a new option for eligible patients who prefer not to inject
Important: do not abruptly stop your GLP-1 medication without speaking to your prescriber. Weight regain after discontinuation begins quickly — a 2026 Lancet analysis found patients regained approximately 60% of prior weight loss within one year of stopping. A conversation with your prescriber before any access change is more useful than a panicked decision after one.
What to avoid: substituting a lower-cost compounded product from an unverified online source. As the compounding legal window closes, some vendors are selling compounded or "research" versions of semaglutide through channels that are not lawful for human use. These products have not been evaluated for quality, sterility, or concentration by any regulatory body.
What remains uncertain
How Hims & Hers will price its branded GLP-1 distribution service relative to standard pharmacy channels is not clear from Q1 2026 disclosures. Whether the distribution model will offer meaningful cost savings compared to using a conventional pharmacy and insurance depends on how the company structures its partnerships.
Broader insurance coverage for GLP-1 medications continues to evolve. Many employer plans still limit access to approved weight-management , and annual plan changes can affect coverage without warning.
Questions to ask your prescriber
- My GLP-1 access is changing — what branded options are covered under my insurance right now?
- Are there manufacturer savings programs or patient assistance programs I should apply for?
- If I need to pause treatment while sorting out access, what should I expect and what is the plan?
The bottom line on access
The compounded GLP-1 window was always temporary. It existed because of a shortage, not as a long-term regulatory pathway for treatment. Now that the shortage has resolved, the legal framework has tightened accordingly.
For patients, the practical effect is higher out-of-pocket costs in the near term, in the absence of broader insurance coverage. If your GLP-1 access is changing, have the conversation with your prescriber before you adjust your dose or stop — not after.
Get the weekly brief
One plain-English email per week on GLP-1s, peptides, and the regulation around them.